Last edited by Voodoogar
Thursday, May 14, 2020 | History

4 edition of Aerosolized ribavirin in the treatment of respiratory syncytial viral infection in children found in the catalog.

Aerosolized ribavirin in the treatment of respiratory syncytial viral infection in children

Aerosolized ribavirin in the treatment of respiratory syncytial viral infection in children

a meta-analysis.

  • 357 Want to read
  • 19 Currently reading

Published by National Library of Canada in Ottawa .
Written in English


Edition Notes

Thesis (M.Sc.) -- University of Toronto, 1995.

SeriesCanadian theses = -- Thèses canadiennes
The Physical Object
FormatMicroform
Pagination1 microfiches : negative. --
ID Numbers
Open LibraryOL17882433M
ISBN 100612075273
OCLC/WorldCa46496536

  The results with ribavirin have been quite mixed. Aerosolized ribavirin has not resulted in reductions in viral shedding or survival benefit in HSCT with PIV pneumonia, while oral or intravenous ribavirin has provided apparent benefit in individual HSCT recipients and hematologic malignancy patients with PIV illness. 48 A recent retrospective Cited by: Peak viral load is at day 12–14 of infection, with virus shed not only in respiratory secretions, but in faeces and other body fluids. Retrospectively devised, but non-validated, scoring systems show that the presence of cough, myalgia, diarrhoea, and rhinorrhoea or sore throat are % sensitive and 76% specific at identifying a patient with.

2. "Younger children have wider airways that make it easier for bacteria to enter and colonize." 3. "Younger children have short and wide eustachian tubes, making them more susceptible to respiratory infections." 4. "Children younger than 3 years usually exhibit worse symptoms because their immune systems are not as developed.". Respiratory syncytial virus is the most common cause of bronchiolitis; nearly every child has been infected by 2 years of age. Seasonal outbreaks occur worldwide, during winter months. Characterized by cough, wheeze, respiratory distress, and hypoxia. Most episodes are mild and self-limited. Trea.

Warning. Oral Ribavirin Ribavirin not effective alone for treatment of chronic HCV infection; do not use ribavirin monotherapy for this indication. Principal toxicity of oral ribavirin is hemolytic anemia which may result in worsening of cardiac disease and has resulted in fatal and nonfatal MI. Do not use ribavirin in patients with a history of clinically / Infection with respiratory syncytial virus, an RNA virus of the genus Pneumovirus, in the family Paramyxoviridae, with a tendency to form syncytia in tissue culture. It causes minor respiratory infection with rhinitis and cough in adults but is capable of causing severe .


Share this book
You might also like
Poems for the wild earth

Poems for the wild earth

Wills Eye Hospital office and emergency room diagnosisand treatment of eye disease

Wills Eye Hospital office and emergency room diagnosisand treatment of eye disease

Photometric methods of analysis

Photometric methods of analysis

Star Pictures

Star Pictures

Successful operating ideas for mine-mill and smelter.

Successful operating ideas for mine-mill and smelter.

Atlas of Polymer Damage

Atlas of Polymer Damage

mental handicap component in social work training

mental handicap component in social work training

story of the Highland Brigade in the Crimea

story of the Highland Brigade in the Crimea

Rent and profit.

Rent and profit.

Bethlehems star

Bethlehems star

Age and source of water in springs associated with the Jacksonville Thrust Fault Complex, Calhoun County, Alabama

Age and source of water in springs associated with the Jacksonville Thrust Fault Complex, Calhoun County, Alabama

Mission tour in the Southwest Pacific

Mission tour in the Southwest Pacific

Law and markets

Law and markets

Research abstracts and reclassification notice

Research abstracts and reclassification notice

Philosophical problems of space and time.

Philosophical problems of space and time.

Aerosolized ribavirin in the treatment of respiratory syncytial viral infection in children Download PDF EPUB FB2

Respiratory syncytial virus (RSV) causes acute respiratory tract illness in persons of all ages. Almost all children are infected by two years of age, and reinfection is common [ 1 ]. The clinical manifestations vary with age, health status, and whether the infection is primary or secondary.

The treatment of RSV in infants, children, and adults. INTRODUCTION. Respiratory syncytial virus (RSV) was first described as ‘acute catarrhal bronchitis’ in 1 It was isolated in and today is responsible for 45%–90% of episodes of bronchiolitis, 15%–35% of pneumonia, 6%–8% of croup, and is also a cause of apnea and otitis media.

More than half of all children are infected by their first birthday. 2 By 2 years of age, more than. PEDIATRIC PHARMACOLOGY AND THERAPEUTICS Early ribavirin syncytial viral children treatment of respiratory infection in high-risk Jessie R.

Groothuis, MD, Kathleen A. Woodin, MD, Robert Katz, MD, Alastair D. Robertson, PhD, John T. McBride, MD, Caroline B. Hall, MD, Bennie C. McWiIliams, MD, and Brian A. Lauer, MD From the Departments of Pediatrics and Biometrics, University of Colorado School Cited by: If the address matches an existing account you will receive an email with instructions to reset your passwordCited by: 1.

Objective: To systematically review the evidence evaluating the efficacy of aerosolized ribavirin for the treatment of infants with respiratory syncytial virus lower respiratory tract infection. Design: A computerized search of MEDLINE from to the present, a review of the reference lists of each retrieved article, and contact with by:   Boeckh M, Englund J, Li Y, et al.

NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients.

Clin Infect Dis. ; 44 Cited by:   Data from multiple retrospective studies suggest that early use of ribavirin oral inhalation (at the URI stage) may be beneficial for the treatment of respiratory syncytial virus (RSV) in adult hematopoietic cell transplant (HCT) recipients and was shown to decrease progression to pneumonia and mortality [Chemaly ], [Shah ]/   Objectives.

To determine the relationship between receipt of aerosolized ribavirin and the hospital course of high-risk infants and children with respiratory syncytial virus (RSV) lower respiratory infection (LRI).

Methods. The – Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV database consists of prospectively enrolled children with acute RSV LRI Cited by: Abstract.

Respiratory syncytial virus (RSV) is the major cause of viral respiratory tract infections in infants and children [1, 2].

The highly contagious nature of the virus means that essentially all children have been infected with RSV by 2 to 3 years of by: 1. In several retrospective studies, ribavirin had no impact on viral shedding, symptom and hospitalization length, progression to LRTI, or mortality in patients with PIV.

60,61 Our own experience with aerosolized ribavirin suggested a moderate reduction in overall mortality, but not in death due to respiratory failure.

13 A recent systematic Cited by: A continuous dosing schedule of aerosolized ribavirin has been used for respiratory syncytial virus (RSV) upper respiratory tract infection and lower respiratory tract infection (LRTI) but is. Aerosolized ribavirin was approved by the FDA for the treatment of RSV LRTI in hospitalized infants and young children in and is the most studied formulation in HCT recipients.

4,5,24,42,   MANAGEMENT OF RESPIRATORY VIRAL INFECTIONS RSV. Management of respiratory viral infections consists of supportive care and, when available, antiviral therapy, especially in patients at high risk of developing LRTIs. Ribavirin is a broad-spectrum nucleoside analogue with activity against DNA and RNA by:   Ventre K, Randolph A () Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children.

Cochrane Database Syst Rev CD Google Scholar Wegner S, Vann JJ, Liu G et al () Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the north carolina Cited by: Treatmentof respiratory syncytial virus (RSV) in infants with bronchiolitis is complicated because of the multifactorial nature of this infection.

The signs and symptoms of RSV result from a combination of direct viral cytopathic effects, host inflammatory responses that lead to airway obstruction and bronchoconstriction. US Pharm. ;39(7):HS2-HS ABSTRACT: Respiratory viruses are increasingly recognized as a cause of community-acquired pneumonia in both children and adults.

Oseltamivir is recommended for the treatment of influenza virus in the inpatient setting, while ribavirin should be considered for the treatment of respiratory syncytial virus in selected infants and children. aerosolized ribavirin is administered to allogeneic transplant patients with lower respiratory tract infection with respiratory syncytial virus (1B).

oral ribavirin may be an alternative in allogeneic transplant patients with lower respiratory tract infection with RSV if aerosolized ribavirin is not available (1C).Cited by: Ribavirin aerosol is currently indicated for the treatment of severe RSV in children. Trials of aerosolized ribavirin for the treatment of severe RSV infection in infants have shown no consistent effect on duration of hospitalization time, mortality or on pulmonary functions.

85 Current guidelines recommend that aerosolized ribavirin be. Hall CB, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection.

A randomized double-blind study. N Engl J Med ; Hall CB, et al. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA ; ribavirin treatment of infants with respiratory syncytial viral infection: A randomized, double blind study.

N Engl J Med ; Smith DW, Frankel LR, Mathers LH, et al: A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection.

N Engl J Med ; Cited by: 1. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. The New England journal of medicine.

Jun 16; (24)–7. [Google Scholar]. Infection with respiratory syncytial virus (RSV; see the image below), which manifests primarily as bronchiolitis or viral pneumonia, is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children.{file}The clinical.

Respiratory syncytial virus (RSV) is the leading cause of pediatric viral respiratory tract infections. The World Health Organization estimates an annual mortality rate of ∼, deaths worldwide []; more inclusive all-cause mortality rates related to RSV approachdeaths [].RSV is also the second leading cause of viral death in elderly individuals [].Cited by: